Article info
PDFCurrent controversy
‘VaxTax’: a follow-up proposal for a global vaccine pandemic response fund
- Correspondence to Julian W März, Institute of Biomedical Ethics and History of Medicine, University of Zurich, Zurich 8006, Switzerland; julian.maerz{at}ibme.uzh.ch
Citation
‘VaxTax’: a follow-up proposal for a global vaccine pandemic response fund
Publication history
- Received June 24, 2022
- Accepted November 7, 2022
- First published November 22, 2022.
Online issue publication
May 18, 2023
Article Versions
- Previous version (28 April 2023).
- You are viewing the most recent version of this article.
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
© Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. http://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.
Other content recommended for you
- Analysis of the institutional landscape and proliferation of proposals for global vaccine equity for COVID-19: too many cooks or too many recipes?
- Vaccine equity in COVID-19: a meta-narrative review
- It is not too late to achieve global covid-19 vaccine equity
- Reserving coronavirus disease 2019 vaccines for global access: cross sectional analysis
- Global access to COVID-19 vaccines: a scoping review of factors that may influence equitable access for low and middle-income countries
- Estimating deaths averted and cost per life saved by scaling up mRNA COVID-19 vaccination in low-income and lower-middle-income countries in the COVID-19 Omicron variant era: a modelling study
- COVID-19 vaccines and the pandemic: lessons learnt for other neglected diseases and future threats
- Addressing sociodemographic disparities in COVID-19 vaccine uptake among youth in Zimbabwe
- Managing the challenges associated with decreasing demand for COVID-19 vaccination in Central and West Asia
- Comparing research and development, launch, and scale up timelines of 18 vaccines: lessons learnt from COVID-19 and implications for other infectious diseases